Abstract
Interferons (IFN) have clinical efficacy in certain hematologic malignancies. Combining IFN with conventional cytotoxic agents has been proposed as a means of improving therapy for diseases such as chronic myelogenous leukemia (CML). In this study, we examined the effect of recombinant interferons alone and in combination with Ara-C on normal and leukemic human hematopoietic progenitor cells (CFU-GM) in vitro. Mononuclear cells from normal bone marrow, peripheral blood of patients with CML, or the acute nonlymphocytic leukemia cell line HL-60 were incubated with α-, β-, or γ-IFN (0-1,000 units/ml) followed by the addition of Ara-C. The survival of normal CFU-GM was significantly increased if cells were treated with IFN 1 h before 3 h of Ara-C exposure. Similar IFN pretreatment of CML and HL-60 progenitors failed to protect leukemic CFU-GM from Ara-C-induced toxicity. This selective protection of normal CFU-GM may have clinical application.
Original language | English (US) |
---|---|
Pages (from-to) | 570-575 |
Number of pages | 6 |
Journal | Journal of Biological Response Modifiers |
Volume | 9 |
Issue number | 6 |
State | Published - 1990 |
Externally published | Yes |
Keywords
- Ara-C
- Chemotherapy
- Granulocyte/macrophage colony-forming cells
- Interferon
- Leukemia
ASJC Scopus subject areas
- Cancer Research
- Immunology
- Pharmacology